Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the […]
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the […]
